This edition of Medtech Insight's Winners & Losers focuses on the medtech businesses of the big diversified medtech companies, including those that also operate in the pharmaceutical market. While companies in this space have limited room for growth, a few stood out for making progress on multiple fronts, while others were not satisfied with results in 2017 so far.
Baxter International Inc. (BAX) is raising its financial outlook for 2017, and through 2020, following continued success in executing its strategy for transforming itself from a drug and device company to a pure device company. Two years ago, the company spun-off its biopharmaceutical business as Baxalta Inc. Inc. to focus on hospital products and renal therapies